Global EditionASIA 中文双语Français
Home / China / Latest

Sinopharm wins approval for inhaled Omicron antibody trials

By Wang Xiaoyu | | Updated: 2022-11-28 19:41
Share - WeChat

Chinese drugmaker Sinopharm said on Monday it has obtained approval to conduct clinical trials of an inhaled monoclonal antibody against the novel coronavirus, a potentially significant weapon against the dominant Omicron variant.

China National Biotech Group, a subsidiary of Sinopharm, received authorization from the National Medical Products Administration on Friday to test a nasal spray utilizing a monoclonal antibody, F61, as a preventive therapy for personnel at high risk of exposure to the virus, according to a statement released by the company.

F61 has demonstrated wide-spectrum neutralizing activities against the original virus and its major strains, including dominant variants in circulation, such as Omicron BA.1, BA.1 .1, BA.2, BA.3, BA.4/5 and BF.7, it said.

An injection version of F61 was approved for human trials on July 22. The first phase of the trial, initiated in Hangzhou on July 28, is near completion, and results have shown a good safety record.

The F61 inhaled spray is easier to use and is expected to trigger protection along nasal mucosa, the first line of defense against respiratory pathogens like the novel coronavirus.

It added the drug candidate has been shown to be safe and effective in real-world studies, and can reduce the rate of infection among close contacts.

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349